Event details

Date

Time

Duration

30 November 2021

15:00PM GMT

1 hour

This open forum discussion will include an exploration of clonal hematopoiesis and of measurable residual disease detection in acute myeloid leukemia.

Join hematopathologists Sanam Loghavi and Kamran Mirza for a focused discussion with expert hematologists Danielle Hammond and Ross Levine. Focusing on clonal hematopoiesis, the conversation will take a deep dive into the science and medicine of the blood – both in the lab and in the clinic.

Key Topics
  • Measurable residual disease detection in acute myeloid leukemia
  • Clonal hematopoiesis

Presenters

Presenter Image

Kamran M. Mirza, MD, PhD, FCAP, FASCP

Associate Professor of Pathology, Medical Education, and Applied Health Sciences Vice-Chair of Education, Department of Pathology and Laboratory Medicine Program Director, Hematopathology Fellowship Founding Program Director, M.S. in Medical Laboratory Science Loyola University Chicago Stritch School of Medicine and Parkinson School of Health Sciences and Public Health

View Bio

Kamran is Associate Professor of Pathology and Medical Education at Loyola University Chicago Stritch School of Medicine where he serves as Vice-Chair of Education and Hematopathology Fellowship Director. An award-winning educator and mentor, Kamran has been recognized in The Pathologist Magazine Power List 100 for 5 consecutive years (2018-2021). He serves on ASCP’s Commission for Continuing Professional Development (CCPD), it's DEI and ASCP Patient Champions committees, and is the founding chair of ASCP’s social media committee. One of the top 10 most followed pathologists on Twitter, Kamran’s research focuses on the molecular basis of hematopoietic neoplasms and novel pedagogical tools for pathology education.

Presenter Image

Sanam Loghavi

Associate Professor of Pathology and Laboratory Medicine at the Department of Hematopathology at MD Anderson Cancer Center.

View Bio

Dr. Loghavi is an Associate Professor of Pathology and Laboratory Medicine at the Department of Hematopathology at MD Anderson Cancer Center. She specializes in hematologic malignancies, in particular myeloid neoplasms and her research interests include molecular risk stratification in hematologic neoplasms and measurable residual disease detection by flow cytometry and next generation sequencing. She is the Medical Director of the ECOG/ACRIN Leukemia Bank at the Central Biorepository and Pathology Facility at MD Anderson and is a co-investigator on several national and internationally run clinical trials for hematologic malignancies.

Presenter Image

Dr. Danielle Hammond

Assistant Professor in the Department of Leukemia, Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center in Houston, Texas.

View Bio

Dr. Hammond is currently an Assistant Professor in the Department of Leukemia, Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center in Houston, Texas. Her clinical and academic focuses include select myeloid neoplasias (AML, MDS, CMML), acquired and constitutional bone marrow failure states, and familial predisposition to leukemias/marrow failure. Dr. Hammond is also involved in the development of a clinical clonal hematopoiesis program, aimed at investigating and mitigating the adverse consequences of this pre-malignant state, including preventing leukemic transformation and the inflammation-mediated diseases of aging, as outlined in her 2021 review article in the journal Pathology.

Dr. Hammond’s other recent original research and review works have been published in: American Journal of Hematology, Current Hematologic Malignancy Reports, Hematology/Oncology Clinics of North America, Leukemia, and Transfusion. She is also the recent recipient of American Society of Hematology (ASH) Abstract Achievement and American Society of Clinical Oncology Conquer Cancer Abstract Merit Awards.

Dr. Hammond enjoys medical education writing, serving 3 years as an editor and contributor to The Microenvironment, a Canadian Hematology Society publication, and writing for the 2020 ASH News Daily. She currently acts as a malignant hematology content expert and continuing medical education contributor to “Figure 1”, a social networking-based education application for healthcare professionals. Her favorite quote is “hematology is the study of blood and the tissues through which it flows.”

Presenter Image

Ross Levine

Chief of the Molecular Cancer Medicine Service, Human Oncology and Pathogenesis Program at Memorial Sloan Kettering (MSK)

View Bio

Ross is Chief of the Molecular Cancer Medicine Service, Human Oncology and Pathogenesis Program at Memorial Sloan Kettering Cancer Center. He is also an Attending Physician on the Leukemia Service, Department of Medicine, the Laurence Joseph Dineen Chair in Leukemia Research and a Professor of Medicine at Weill Cornell Medical College. His lab focuses on elucidating the genetic basis of myeloid malignancies, and using this knowledge to improve outcomes for patients with these disorders. His primary research interests include the role of JAK-STAT signaling in malignant transformation and in the effects of mutations in epigenetic modifiers in clonal hematopoiesis, MPN, and AML. Moreover, as a physician-scientist, his lab has a specific interest in translating this knowledge back to the clinic and in participating in the preclinical and clinical evaluation of targeted therapies for leukemia patients.

Registration

Our registration process uses cookies, by submitting this registration form you agree to our cookie policy.